Close to 50 companies are offering a variety of analytical testing solutions for the asse
Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions, claims Roots Analysis Over time, pharmaceutical players have demonstrated significant interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of these novel biomarkers.
Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions. To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link The USD 860 million (by 2030) financial opportunity within the cancer biomarkers market has been analyzed across the following segments: The Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030 report features the following companies, which we identified to be key players in this domain: Table of Contents To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html Contact Details Gaurav Chaudhary +1 (415) 800 3415
[email protected] Source: Free Articles from ArticlesFactory.com Several companies have already developed / are developing analytical tests for novel cancer biomarkers (TMB, MSI / MMR and TILs), intended to assist physicians in making personalized treatment decisions.
.